Contingent screening for Down syndrome - Results from the FaSTER trial

Prenatal Diagnosis

Volumn 28, Issue 2, 2008, Pages 89-94

  Cuckle, Howard S ^a,n   Malone, Fergal D ^b   Wright, David ^c   Porter, T Flint ^d   Nyberg, David A ^e   Comstock, Christine H ^f   Saade, George R ^g   Berkowitz, Richard L ^a   Ferreira, Jose C ^h   Dugoff, Lorraine ⁱ   Craigo, Sabrina D ^j   Timor, Ilan E ^k   Carr, Stephen R ^l   Wolfe, Honor M ^m   D'Alton, Mary E ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SWEDISH MEDICAL CENTER   (United States)

^f WILLIAM BEAUMONT HOSPITAL   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j TUFTS UNIVERSITY   (United States)

^k NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^l BROWN UNIVERSITY   (United States)

^m UNIVERSITY OF NORTH CAROLINA   (United States)

ⁿ NewYork Presbyterian Hospital   (United States)

more..

Author keywords

Contingent; Down syndrome; Markers; Policy; Screening

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; INHIBIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; DISEASE MARKER; DOWN SYNDROME; FEMALE; HIGH RISK PREGNANCY; HUMAN; MATERNAL SERUM; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL SCREENING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY;

BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MASS SCREENING; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 39749142076     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1913     Document Type: Article

References (18)

1. Benn P, Wright D, Cuckle H. 2005. Practical strategies in contingent sequential screening for Down's syndrome. Prenat Diagn 25(8): 645-652.
2. Christiansen M, Larsen SO. 2002. An increase in cost-effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing. Prenat Diagn 22: 482-486.
3. Cuckle HS. 1995. Improved parameters for risk estimation in Down's syndrome screening. Prenat Diagn 15: 1057-1065.
4. Cuckle H. 2001. Integrating Down's syndrome screening. Curr Opin Obstet Gynaecol 13(2): 175-181.
5. Cuckle H. 2003. Updated modeling parameters for Down syndrome screening. Balkan J Med Genet 6(2&3)(Suppl.): 101-107.
6. Cuckle HS, van Lith JMM. 1999. Appropriate biochemical parameters in first trimester screening for Down's syndrome. Prenat Diagn 19(6): 505-512.
7. Cuckle H, Arbuzova S. 2002. The efficiency and clinical practicality of multi-modality screening strategies. In Early Prenatal Diagnosis, Fetal Cells and DNA in the Mother: Proceedings of the 12th Fetal Cell Workshop, Macek M, Bianchi D, Cuckle H (eds). Charles University Press: Prague; 387-397.
8. Cuckle H, Arbuzova S. 2004. Multianalyte maternal serum screening for chromosomal defects. In Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment (5th edn), Milunsky A (ed.). Johns Hopkins University Press: Baltimore, USA; 795-835.
9. Cuckle HS, Wald NJ, Thompson SG. 1987. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94: 387-402.
10. Cuckle H, Benn P, Wright D. 2005. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatal 29: 252-257.
11. Evans MI, Krantz DA, Hallhan TW, Galen RS. 2007. Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotrophin significantly outperforms intact human chorionic gonadotrophin in a multimarker protocol. Am J Obset Gynecol 196(3): 198-205.
12. Herman A, Dreazen E, Tovbin J, Weinraub Z, Bukovsky Y, Maymon R. 2002. Comparison between disclosure and non-disclosure approaches for trisomy 21 screening tests. Hum Reprod 17(5): 1358-1362.
13. Knight GJ, Palomaki GE, Neveux LM, et al. 2005. Integrated serum screening for Down syndrome in primary obstetric practice. Prenat Diagn 25(12): 1162-1167.
14. Malone FD, Canick JA, Ball RH, et al. 2005. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 353(19): 2001-2011.
15. Maymon R, Cuckle H, Jones R, Reish O, Herman A. 2005. Predicting the result of additional second trimester markers from a woman's first trimester marker profile: a new concept in Down's syndrome screening. Prenat Diagn 25(12): 1102-1106.
16. Pandya PP, Jones P, Huttley W, Rodeck C, Wald N. 2006. Integrated screening for Down syndrome in routine clinical practice. Ultrasound Obset Gynecol 28(4): 362-363.
17. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. 2003. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10(2): 56-104.
18. Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. 2004. Contingent screening for Down's syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 24(10): 762-766.